| ORIGINAL ARTICLE |
|
| Year : 2018 | Volume
: 5
| Issue : 2 | Page : 96-102 |
|
|
A study of comparison of PUVASOL and NBUVB in patients with vitiligo
Vaaruni Ravishankar1, Santoshdev P Rathod2, Siddhartha Saikia2, Raju G Chaudhary2, Rekha B Solanki2
1 Department of Dermatology, Chettinad Hospital and Research Institute, Chennai, Tamil Nadu, India
2 Department of Dermatology, Smt. NHL Municipal Medical College, VS Hospital, Ahmedabad, Gujarat, India
Correspondence Address:
Dr. Vaaruni Ravishankar
C, 23, Srinidhi, Fourth Main Road, Indira Nagar, Adyar, Chennai 600020, Tamil Nadu
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/Pigmentinternational.Pigmentinternational_
|
|
|
Introduction: Vitiligo is an acquired, hypomelanotic disease, characterized by circumscribed depigmented macules. Phototherapy, which is the use of ultraviolet irradiation with or without exogenous photosensitizer is a well established treatment option. Psoralens with sunlight as the source of ultraviolet A-rays is known as PUVASOL. Narrow band Ultraviolet B phototherapy (NBUVB; 311–313 nm) has been introduced over the past decade. Aims: To study the clinical effectiveness and assess the safety of NBUVB and PUVASOL therapy in Vitiligo patients. Methods: The patients were randomly allocated in to two groups containing 25 patients each. Group A patients received NBUVB with an initial dose of 250 mJ/cm2, incremented by 20% with each subsequent visit till optimum dose was achieved, twice a week on non-consecutive days. Group B patients received PUVASOL-oral Trimethylpsoralen or topical 0.2% w/w Trioxsalen followed by exposure to sunlight, twice a week on non-consecutive days. The extent of repigmentation was documented at regular intervals upto 6 months. Results: Amongst patients receiving NBUVB and PUVASOL, 56% and 48% had ≥50% repigmentation respectively. Disease was unstable in 48% and 36% of patients prior to commencement of therapy which reduced to 12% and 16% after therapy, respectively. 16% and 36% of the patients experienced side effects and 76% and 48% showed excellent colour match of the repigmented patches respectively. Conclusion: While both PUVASOL and NBUVB are both good therapeutic options; NBUVB therapy is found to be more effective and more cosmetically acceptable, with better colour matching of lesions and minimal adverse effects.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
